Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juan Ronderos

Neurological Surgery Fairhope, AL Medical Doctor

NPI 1407875016 CMS profile 63895

8096 Twin Beech Rd Ste 250, Fairhope, AL 36532

Open in the dashboard

General payments

$38,903

126 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Juan Ronderos of Fairhope, AL is reported in the CMS Open Payments database as having received $38,903 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $193 6
2024 General $98 4
2023 General $907 6
2022 General $6,113 32
2021 General $18,057 30
2020 General $5,260 18
2019 General $8,276 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Ronderos
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Juan Ronderos were reported at $193. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Juan Ronderos Neurological Surgery median Middle half National median
2019 $8,276 $582 $138–$3,006 $163
2020 $5,260 $294 $76–$2,174 $114
2021 $18,057 $387 $105–$2,432 $132
2022 $6,113 $542 $139–$2,989 $149
2023 $907 $534 $145–$2,697 $160
2024 $98 $574 $155–$3,046 $164
2025 $193 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Precision Spine, Inc. $16,351 12 payments
  2. Orthofix Medical, Inc. $13,137 11 payments
  3. Curiteva, Inc. $4,531 5 payments
  4. Globus Medical, Inc. $2,109 14 payments
  5. Baxter Healthcare $569 13 payments
  6. Spinal Elements, Inc. $458 6 payments
  7. AbbVie, Inc. $313 16 payments
  8. Medtronic, Inc. $209 9 payments
  9. GT Medical Technologies, Inc $186 3 payments
  10. Carl Zeiss Meditec USA, Inc. $127 1 payment
  11. Other $914 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $25,429 19 payments
  2. Food and Beverage $4,896 99 payments
  3. Travel and Lodging $4,401 2 payments
  4. Consulting Fee $4,000 3 payments
  5. Entertainment $133 2 payments
  6. Gift $44 1 payment
Products named General payments · program years 2019–2025
  1. SLIMPLICITY HP Orthopedics $12,414 8 payments
  2. FORZA $7,500 1 payment
  3. NEXGEN ANTERIOR CERVICAL PLATE SYSTEM $5,425 2 payments
  4. LONESTAR Cervical Stand Alone (CSA) $4,448 8 payments
  5. SLIM HP ACDF $2,000 1 payment
  6. CREO $1,705 2 payments
  7. LONESTAR $1,189 2 payments
  8. C SPINE SYSTEM $1,000 1 payment
  9. Pedicle Screw System $1,000 1 payment
  10. SLIMPLICITY HP Orthopedics $661 2 payments
  11. Other $3,270 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

155

Median for Neurosurgery: 83

Drug cost

$1,379

Median for Neurosurgery: $872

Branded share of claims

47.1%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 61 $547
Celecoxib Generic 16 $256
Pregabalin Generic 18 $245
Methylprednisolone Generic 24 $166
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $68
Ondansetron Hcl Generic 11 $58
Tramadol Hcl Generic 13 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$42,469

Medicare's payments for the services billed

Medicare patients

98

Average age 74

Services billed

202

56 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 41%
Diabetes 35%
Depression 31%
Atrial fibrillation 22%
COPD 21%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record